# An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events

> **NCT07503028** · EARLY_PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Celregen Therapeutics** · enrollment: 10 (estimated)

## Conditions studied

- T1DM - Type 1 Diabetes Mellitus
- Pancreatogenic Diabetes Mellitus

## Interventions

- **DRUG:** CRG002

## Key facts

- **NCT ID:** NCT07503028
- **Lead sponsor:** Celregen Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-10-17
- **Primary completion:** 2028-01-18
- **Final completion:** 2028-01-18
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07503028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07503028, "An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07503028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*